歌禮製藥-B(01672.HK)治療痤瘡藥物III期臨床試驗快將啟動
歌禮製藥-B(01672.HK)公布,在德國柏林召開的歐洲皮膚病與性病學會(EADV)2023年大會上以壁報形式展示同類首創脂肪酸合成(酉每)(FASN)抑制劑ASC40治療痤瘡的II期研究頂線結果。
總體而言,三種劑量的ASC40與安慰劑相比均顯示出良好的療效。ASC40的療效在50毫克劑量中達到最大。
該項研究頂線結果顯示,每日口服一次ASC40、治療12周的安全性和耐受性良好。ASC40顯著改善總皮損、炎性皮損和IGA (研究者整體評估)治療成功率。該項II期研究的療效和安全性評估為III期臨床試驗提供支持,III期臨床試驗將很快啟動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.